Tikva Allocell joins the Johnson & Johnson Innovation – JLABS community

Tikva Allocell joins the Johnson & Johnson Innovation – JLABS community

SINGAPORE – 18 Mar 2024 – Tikva Allocell Pte Ltd (“Tikva” or the “Company”), a Singapore-based preclinical stage biotechnology company developing ‘off-the-shelf’ cell therapy targeting solid tumors today announced it is joining the Johnson & Johnson Innovation – JLABS community.

Tikva’s allogeneic cell therapy platform leverages the clinically proven established safety profile of virus-specific T cells and uses novel protein and cell engineering techniques to further enhance cell persistence and anti-tumor activity. The Company is founded by Dr. Ivan Horak, with over 20 years’ experience in the global pharmaceutical industry. Co-founders and scientific advisors of the Company include Dr. Malcolm Brenner, Dr. Cliona Rooney and Dr. Helen Heslop, who are professors at the Center for Cell and Gene Therapy, Baylor College of Medicine. Dr. Brenner and Dr. Heslop are also members of the National Academy of Medicine. Tikva is developing an innovative pipeline of cell therapies for the treatment of various types of hard-to-treat solid tumors.

Joining JLABS allows the Company access to resources, mentorship, and collaboration opportunities in one of the largest global networks of research and development innovation ecosystems. Founder and Chief Executive Officer Dr. Ivan Horak stated, “By targeting aggressive solid tumors with first-in-class allogeneic cell therapy products, Tikva Allocell aims to bring innovative solutions to patients with unmet medical needs. We believe that the support of JLABS will further increase our chances of success in creating impactful treatments for patients.”  

About Tikva Allocell

Tikva Allocell Pte Ltd is a late preclinical stage biotech company headquartered in Singapore. Our cell therapy platform is an off-the-shelf CAR-T therapy, utilizing highly specific second-generation allogeneic T cells prepared from the blood of Epstein-Barr virus (EBV)-positive healthy individuals. Our approach exploits the intrinsic properties of Virus-Specific T cells (VSTs), enhanced by IP-protected novel repurposing strategies to enhance cell performance and safely target patients with solid tumors including gastric, prostate and triple negative breast cancers.

For more information on Tikva, please visit www.tikvaallocell.com.

Investors and Media Contact

Wilson W. Cheung

Share the Post:

Related Posts